Supernus Pharmaceuticals (SUPN) Assets Average (2012 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Assets Average of $1.5 billion for Q2 2026, up 7.3% year-over-year from $1.4 billion in Q2 2025, and down 0.83% on a QoQ basis from $1.5 billion in Q1 2026.
Supernus Pharmaceuticals (SUPN) Assets Average (2012 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Assets Average for 15 years, with the latest figure at $1.5 billion in Q2 2026.
- Assets Average for Q2 2026 came in at $1.5 billion, up 7.3% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 7.3% YoY), and the FY2025 annual result was $1.4 billion, up 6.61% from the prior year.
- Assets Average declined to $1.5 billion in Q2 2026, from $1.5 billion in the prior quarter.
- Over five years, Assets Average peaked at $1.7 billion in Q1 2023 and troughed at $1.3 billion in Q4 2023.
- A 5-year average of $1.5 billion and a median of $1.4 billion in 2025 frame the typical range for Assets Average.
- The widest annual swing landed in 2022, when Assets Average increased 10.53%; it then slipped 26.12% in 2024.
- A 5-year view of Assets Average shows it stood at $1.7 billion in 2022, then declined by 24.53% to $1.3 billion in 2023, then grew by 5.77% to $1.4 billion in 2024, then grew by 5.96% to $1.4 billion in 2025, then rose by 1.96% to $1.5 billion in 2026.
- Per Business Quant data, the three most recent Assets Average figures were $1.5 billion in Q2 2026, $1.5 billion in Q1 2026, and $1.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 39.95 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 15.12 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 98.59 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.97 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 35.94 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 5.13 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 13.39 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 5.97 Bn |
| 10 | Supernus Pharmaceuticals | 2.75 Bn | 2.38 Bn | 185.39 Mn | 1.46 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.46 Bn |
| Mar 31, 2026 | 1.48 Bn |
| Dec 31, 2025 | 1.44 Bn |
| Sep 30, 2025 | 1.40 Bn |
| Jun 30, 2025 | 1.36 Bn |
| Mar 31, 2025 | 1.36 Bn |
| Dec 31, 2024 | 1.36 Bn |
| Sep 30, 2024 | 1.33 Bn |
| Jun 30, 2024 | 1.31 Bn |
| Mar 31, 2024 | 1.29 Bn |
| Dec 31, 2023 | 1.28 Bn |
| Sep 30, 2023 | 1.29 Bn |
| Jun 30, 2023 | 1.54 Bn |
| Mar 31, 2023 | 1.75 Bn |
| Dec 31, 2022 | 1.70 Bn |
| Sep 30, 2022 | 1.69 Bn |
| Jun 30, 2022 | 1.67 Bn |
| Mar 31, 2022 | 1.66 Bn |
| Dec 31, 2021 | 1.62 Bn |
| Sep 30, 2021 | 1.56 Bn |